Company: EHC
Filing Date: 2025-10-31
Form Type: 10-Q
Source: 0000785161-25-000115
Chunk: 60

Company: Encompass Health Corp
Filing Date: 2025-10-31
Form: 10-Q
Item: Part I, Item 1
Chunk 60
---
 impairment impact on noncontrolling interests— — — 7.3 Income from continuing operations before income tax expense$219.9 $183.8 $695.3 $548.2 

18

Encompass Health Corporation and SubsidiariesNotes to Condensed Consolidated Financial Statements

Additional detail regarding the revenues of our operating segment by service line follows (in millions):Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Net operating revenues:Inpatient$1,427.3 $1,316.2 $4,258.7 $3,864.4 Outpatient and other50.2 34.8 131.9 103.8 Net operating revenues$1,477.5 $1,351.0 $4,390.6 $3,968.2 Equity in net income of nonconsolidated affiliates and the Provision for income tax expense are reported on our condensed consolidated statements of operations. Segment assets are reported on our condensed consolidated balance sheets as Total assets. Segment capital expenditures are reported on our condensed consolidated statements of cash flows as Purchases of property, equipment, and intangible assets.

19

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) relates to Encompass Health Corporation and its subsidiaries and should be read in conjunction with our condensed consolidated financial statements included under Part I, Item 1, Financial Statements (Unaudited), of this report. In addition, the following MD&A should be read in conjunction with our audited consolidated financial statements for the year ended December 31, 2024, Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, Part I, Item 1, Business, and Item 1A, Risk Factors, included in our Annual Report on Form 10-K for the year ended December 31, 2024 filed on February 28, 2025 (collectively, the “2024 Form 10‑K”).

This MD&A is designed to provide the reader with information that will assist in understanding our condensed consolidated financial statements, the changes in certain key items in those financial statements from period to period, and the primary factors that accounted for those changes, as well as how certain accounting principles affect our condensed consolidated financial statements. See “